RepliCel is a regenerative medicine company focused on aesthetics and orthopedics. Our cell therapy products are tailor-made to restore cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. Our next-generation dermal injection technology is designed to revolutionize aesthetic treatment outcomes. RepliCel is dedicated to improving everyday lives.
RepliCel is developing several products from two unique cell therapy populations both taken from the hair follicles embedded in a small skin biopsy taken from the back of a patient's head.
RepliCel is also developing a medical device based on several patent-protected technologies related to improving patient injections.
The products currently RepliCel is currently developing are:
- RCH-01 – Cell therapy for pattern baldness
- RCS-01 – Cell therapy for aging or sun damaged skin
- RCT-01 – Cell therapy for tendon degeneration
- RCI-02 – Next-generation dermal injection device
RepliCel was founded on the work of two European researchers investigating the cell biology of the hair follicle: Kevin McElwee, PhD and Rolf Hoffmann, MD. RepliCel is a publicly traded company, headquarted in Canada leading the development of four products with active programs in Canada, Europe, Japan, Greater China, and the United States.
The Company is purpose-built to develop high-value assets it commercializes with established partners such as it already has in place in certain Asian countries.
RepliCel is structured to be lean and virtual by leading the development of its products through a trusted network of contract research, manufacturing, and advisors.